^
    1d
    Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma (clinicaltrials.gov)
    P=N/A, N=144, Recruiting, University Health Network, Toronto | N=80 --> 144 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, TCRx Therapeutics Co.Ltd
    New P1 trial
    1d
    WF-1804CD: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (clinicaltrials.gov)
    P=N/A, N=600, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    1d
    Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma. (PubMed, Virchows Arch)
    In conclusion, our findings suggest that c-Myc overexpression and MYC rearrangement are associated with ibrutinib resistance in MCL. Detecting MYC rearrangement in selected MCL cases could be critical for optimizing treatment strategies and improving patient outcomes.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Imbruvica (ibrutinib)
    1d
    A Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory Parameters. (PubMed, Neuro Oncol)
    The ABLE risk-stratification model can effectively differentiate prognostic subgroups in patients with PCNSL.
    Journal
    |
    B2M (Beta-2-microglobulin)
    |
    methotrexate • methotrexate IV
    1d
    Reveal the regulatory role of DDX10 in diffuse large B-cell lymphoma: binding with FBL to promote cell proliferation and invasion. (PubMed, Mol Cell Probes)
    DDX10 contributes to the proliferation and invasion of DLBCL cells via positively regulating FBL, highlighting the DDX10-FBL axis as a potential therapeutic target. This work provides new insights into DLBCL pathogenesis and underscores the biomedical relevance of targeting DDX10-FBL.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • DDX1 (DEAD-Box Helicase 1) • DDX10 (DEAD-Box Helicase 10)
    1d
    FOLLOW: French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Apr 2025
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    BCL2 (B-cell CLL/lymphoma 2)
    1d
    PD-L1 PET-imaging During CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University Medical Center Groningen | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Dec 2025
    Enrollment closed • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab)
    1d
    B cell-intrinsic interleukin 17 receptor A signaling supports the establishment of chronic murine gammaherpesvirus 68 infection. (PubMed, J Virol)
    In this study, we developed a new mouse model to understand the B cell-intrinsic role of IL-17RA signaling in gammaherpesvirus infection. Previous studies have shown that IL-17RA signaling is proviral in the context of gammaherpesvirus infection, and this study found that while B cell-intrinsic IL-17RA signaling is not the sole factor behind the systemic proviral role of IL-17RA signaling, it plays an important role in the virus-driven germinal center response, the expansion of B-1 B cells, and the establishment of chronic gammaherpesvirus infection.
    Preclinical • Journal
    |
    IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A)
    2d
    Anaplastic Large Cell Lymphoma Related to Breast Implant Presenting as a Solid mass: A Case Report. (PubMed, Case Rep Surg)
    Patient education and a multidisciplinary team approach allow for timely diagnosis and complete surgical excision, which are key for a good prognosis. Clinical and radiological surveillance detect early recurrence and assess need for adjuvant therapy.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    2d
    Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. (PubMed, Front Immunol)
    Despite containing SLL deposits, the harvested melanoma produced a CD8+ T cell-predominant tumor-reactive TIL infusion product containing stem-like CD39negCD69neg CD8+ T cells. A strong overlap (60%) in the TCRβ sequences between this infusion product and peripheral blood mononuclear cells collected at the 9-month follow-up visit was evidence of long-term persistence of TIL in this patient.
    Journal • Tumor-infiltrating lymphocyte
    |
    CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • ITGAX (Integrin Subunit Alpha X) • TRB (T Cell Receptor Beta Locus)
    2d
    BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas (clinicaltrials.gov)
    P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone